Skip to main content

Find Clinical Trials

Home
Conditions
Hepatitis C

Clinical trial condition

Hepatitis C

Explore clinical trials studying Hepatitis C. Study availability and eligibility vary by location and protocol.

749 public trials 21 recruiting studies

Refine in advanced search Browse all conditions

Hepatitis C trial results

Completed

MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)

NCT00857311

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: Not specified

View Trial Details

Completed

Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)

NCT00518622

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: Not specified

View Trial Details

Completed

Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C

NCT01740089

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: Moscow State University of Medicine and Dentistry Moscow, Russia

View Trial Details

Completed

Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)

NCT00724893

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Not specified

View Trial Details

Completed

Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis

NCT01909778

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +12 more
Locations: 1220.15.49006 Boehringer Ingelheim Investigational Site Mainz, Germany

View Trial Details

Completed

Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

NCT01637922

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: 1220.57.0001 Boehringer Ingelheim Investigational Site Atlanta, Georgia, United States

1220.57.0002 Boehringer Ingelheim Investigational Site Overland Park, Kansas, United States

1220.57.0003 Boehringer Ingelheim Investigational Site Salt Lake City, Utah, United States

View Trial Details

Completed

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

NCT01579474

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: 1220.54.08104 Boehringer Ingelheim Investigational Site Chuo-ku, Chiba, Japan

1220.54.08118 Boehringer Ingelheim Investigational Site Chuo-ku, Kobe, Hyogo, Japan

1220.54.08108 Boehringer Ingelheim Investigational Site Fukui, Fukui, Japan

1220.54.08110 Boehringer Ingelheim Investigational Site Gifu, Gifu, Japan

View all 24 locations

View Trial Details

Completed

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

NCT01704846

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: 1220.53.08101 Boehringer Ingelheim Investigational Site Sumida-ku,Tokyo, Japan

View Trial Details

Completed

Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment

NCT01580306

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: 1220.58.1 Boehringer Ingelheim Investigational Site Kiel, Germany

View Trial Details

Completed

Behavioral Science Aspects of Rapid Test Acceptance

NCT01317784

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Blood-Borne Infections, +22 more
Locations: Center for Behavioral Research and Services Long Beach, California, United States

View Trial Details